Genomic Insights into Innate Resistance in Early-Stage <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Comprehensive Analysis of Next-Generation Sequencing Data
Genomic heterogeneity in EGFR-mutant NSCLC arises early in tumorigenesis. The comparable TMB and lower VAF of EGFR mutations in early-stage disease suggest that innate resistance to EGFR-TKIs may be driven by concurrent GAs, supporting the consideration of combination therapies even in early-stage EGFR-mutant NSCLC.
Authors
- Ahrong Kim (ORCID: https://orcid.org/0000-0003-2317-8920)
- Jung Seop Eom (ORCID: https://orcid.org/0000-0002-0832-1314)
- Hayoung Seong
- Mi‐Hyun Kim (ORCID: https://orcid.org/0000-0002-6527-6804)
- Ju Sun Song (ORCID: https://orcid.org/0000-0003-4607-872X)
- Soo Han Kim (ORCID: https://orcid.org/0000-0002-4549-0862)
Institutions
- Genome and Company (South Korea) (KR)
- Pusan National University Hospital (KR)
- Pusan National University (KR)
Publication Details
- Journal
- Cancer Research and Treatment
- Published
- 2025-08-25
- DOI
- https://doi.org/10.4143/crt.2025.114
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pusan National University
- Pusan National University Hospital